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Abstract Amyotrophic lateral sclerosis (ALS) is a progres-
sive and incurable neurodegenerative disease. Although sev-
eral compounds have shown promising results in preclinical
studies, their translation into clinical trials has failed. This
clinical failure is likely due to the inadequacy of the animal
models that do not sufficiently reflect the human disease.
Therefore, it is important to optimize drug target selection
by identifying those that overlap in human and mouse pathol-
ogy. We have recently characterized the transcriptional pro-
files of motor cortex samples from sporadic ALS (SALS)
patients and differentiated these into two subgroups based
on differentially expressed genes, which encode 70 potential
therapeutic targets. To prioritize drug target selection, we in-
vestigated their degree of conservation in superoxide dismut-
ase 1 (SOD1) G93A transgenic mice, the most widely used
ALS animal model. Interspecies comparison of our human
expression data with those of eight different SOD1G93A
datasets present in public repositories revealed the presence
of commonly deregulated targets and related biological pro-
cesses. Moreover, deregulated expression of the majority of
our candidate targets occurred at the onset of the disease,
offering the possibility to use them for an early and more
effective diagnosis and therapy. In addition to highlighting
the existence of common key drivers in human and mouse
pathology, our study represents the basis for a rational preclin-
ical drug development.
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Background
Amyotrophic lateral sclerosis (ALS), sometimes called Lou
Gehrig’s disease, is a fatal neurodegenerative disorder caused
by the loss of both upper and lower motoneurons.
Approximately 10% of ALS cases is familial (FALS), mainly
with an autosomal dominant inheritance pattern, while the
majority of cases (90%) occurs sporadically (SALS), caused
by complex interaction between multiple genetic variants and
environmental factors (Mitchell and Borasio 2007).
Although, over the last years, several studies have been
conducted to develop effective therapeutic interventions,
ALS remains a progressive and incurable disease (Pasinelli
and Brown 2006; Ferraiuolo et al. 2011). In fact, the only
approved treatment, riluzole, improves survival of ALS pa-
tients but only to a modest extent, whereas several other phar-
macologic agents, apparently promising when tested in animal
models, have failed when translated into clinical practice
(Turner et al. 2001). This may be due to poor knowledge of
ALS pathophysiology and the use of inadequate animal
models.
During the last 20 years, the most popular animal model of
ALS has been the superoxide dismutase 1 G93A transgenic
mouse (SOD1G93A), overexpressing human SOD1 with a
causative mutation (a glycine to alanine substitution at posi-
tion 93), which results in a toxic gain of SOD1 function (Dal
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Canto and Gurney 1994; Achilli et al. 2005). Although the use
of this and other animal models (e.g., TDP-43, TAU P301L,
and Wobbler mice) has provided invaluable tools for ALS
research, they do not faithfully reproduce the complexity
and heterogeneity characterizing the human disease. It is evi-
dent, therefore, that there is a need to use research strategies
that allow to optimize the identification and selection of clin-
ically useful therapeutic targets overcoming the current dis-
connection between preclinical studies and the translation of
these results into clinical practice (Perrin 2014; McGoldrick
et al. 2013).
The advent of high-throughput experimental technologies,
such as DNA microarray, has revolutionized the field of bio-
logical research, becoming one of the major methods to elu-
cidate the transcriptional features of many complex diseases,
such as ALS, and to identify/prioritize new pharmacological
targets (Lederer et al. 2007a; Morello et al. 2015; Paratore
et al. 2006; Cavallaro et al. 2012). To this regard, our research
group has recently characterized the transcriptional profiles of
motor cortex samples from SALS patients and differentiated
these into two gene expression-based subgroups (SALS 1 and
SALS2), revealing new clues to the molecular pathogenesis
and novel potential predictive biomarkers and therapeutic tar-
gets (Aronica et al. 2015; Morello and Cavallaro 2015).
The aim of the present study is to investigate the degree of
conservation of the previously identified molecular targets
(Aronica et al. 2015; Morello and Cavallaro 2015) in
SOD1G93A transgenic mice, in order to prioritize their possible
selection for a subsequent validation. The use of a meta-
analytic approach offers a unique opportunity to significantly
increase the statistical power of any individual microarray
study, thus enabling identification of more reliable molecular
biomarkers and targets. Moreover, to better characterize the
role of candidate target genes in ALS pathophysiology, we
have interpreted data in the context of Gene Ontology (GO)
annotations and known biological pathways.
Methods
The analysis workflow is shown in Fig. 1 and described
below.
Dataset Selection and Preprocessing
In our previous work (Aronica et al. 2015), we analyzed genes
and pathway differentially deregulated in the motor cortex of
two subgroups of SALS patients compared with controls. The
analysis of altered networks of biological molecules in SALS
has enabled to identify genes encoding potential therapeutic
targets by combining various drug repositories (e.g.,
Metacore; Clinical Trials.gov; DrugBank; PubChem). In
particular, we selected genes encoding proteins that were
primary targets of drugs currently used in preclinical or
clinical stages for treating several clinical diseases, giving
greater emphasis to those that showed encouraging results
for the treatment of neurodegenerative disorders (Aronica
et al. 2015; Morello and Cavallaro 2015).
In order to identify common genomic changes between
human ALS and SOD1G93A transgenic mouse model, in this
work, we compared expression changes of our human gene
target list with those of their corresponding homologs in
SOD1G93A transgenic mice present in public repositories. To
do it, we searched the public data repositories NCBI GEO
(http://www.ncbi.nlm.nih.gov/geo/) and ArrayExpress
(http://www.ebi.ac.uk/arrayexpress/) for gene expression
microarray data sets using the following search terms and/or
their combinations: Bamyotrophic lateral sclerosis^, Bmotor
neuron disease^, BSOD1 mouse model^, BSOD1G93A trans-
genic mouse^ and Bexpression profiling^. Data sets included
in the analysis had to meet the following criteria: (1) data were
acquired using a genome-wide gene expression microarray
platform with accessible and clear probe-to-gene mapping an-
notations and (2) there were ≥3 replicates for each experimen-
tal condition. In particular, we utilized only gene expression
data obtained from isolated motor neurons and/or spinal cord
homogenates from wild-type littermates and SOD1G93A mice
at various disease stages (presymptomatic, symptomatic and
terminal stage). Overall, for each dataset, the following infor-
mation were extracted: GEO or ArrayExpress accession num-
ber, title, year of publication, reference, platform, number of
samples (transgenic mice and controls), stage of disease, sam-
ple type and gene expression data (Table 1).
For each mouse dataset, raw intensity values were
thresholded to 1, log2-transformed, normalized, and baselined
to the median of all samples by using GeneSpring GX v13.1
software package (Agilent Technologies). Affymetrix gene
expression data were Robust Multichip Average (RMA) proc-
essed using quantile normalization, while Agilent and
Illumina data were normalized to the 75th percentile
(Cavallaro et al. 2002; Cavallaro et al. 2004).
Meta-Analysis of Gene Expression Data
To perform interspecies comparison, we built a unique, com-
prehensive dataset where human and mouse gene expression
data were aggregated. In particular, this dataset included ex-
pression changes of 70 differentially expressed genes
encoding potential therapeutic targets, previously character-
ized in SALS patients, together with their corresponding ho-
mologs in mouse. To create this dataset, we firstly associated
microarray probe IDs from each dataset to corresponding
NCBI Entrez human or mouse gene IDs and symbols by using
Homo sapiens GRCh38 and Mus musculus GRCm38.p2
(Maglott et al. 2005). When multiple probes corresponded to
the same gene, gene expression values were averaged. Then,
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fold change values for human (SALS patients versus control)
and mouse (SOD1G93A mice versus littermate control groups)
were calculated and converted into the negative reciprocal if
the fold change was less than 1. Moreover, gene IDs from
mouse studies were annotated with the corresponding human
homologs, when available, using NCBI HomoloGene data-
base (build version 68) (Wheeler et al. 2008). All the above-
described analyses were performed by using homemade func-
tions in PostgreSQL environment (version 9.4.5; http://www.
postgresql.org/).
To assess the statistical significance of common genomic
changes observed in terminal stages of both human and ALS
animal models, statistical analysis of gene expression data
from 120-day-old SOD1G93A transgenic mice was performed
by using GeneSpring GX v13.1 software package (Agilent
Technologies). Genes with a corrected P value <0.05 (one-
way ANOVA followed by the Benjamin-Hochberg false dis-
covery rate and the Tukey’s post hoc test) were deemed to be
statistically significant.
For a graphical representation of fold regulation expression
data, heat maps and time-course plots were generated by using
the R packages Bheatmap.2^ and Bggplot2^ (R Core Team,
2012; https://www.r-project.org). Two different types of distance-
based hierarchical clustering were also performed by using
the Bhclust^ function in R. The first was based on the
Euclidean distance of average fold change values represented
in linear scale using complete linkage method as parameter
(Ward 1963). The secondwas based on the semantic similarity
Fig. 1 Schematic representation
of proposed meta-analysis-based
drug target selection and
prioritization. The workflow
depicts the steps performed in this
study, from data acquisition to the
visualization and export of results
in various output formats. See
BMethods^ section for details.DE
differentially expressed,GOGene
Ontology
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among the GO terms for biological processes and gene prod-
ucts and was determined by using the GOSemSim R package
(Yu et al. 2010).
To interpret the biological significance of selected candi-
date targets, GO terms and pathways enrichment analyses
were performed using Metacore (Thomson Reuters)
(Nikolsky et al. 2009). P values were obtained from the basic
formula for hypergeometric distribution and corrected by a
false discovery rate threshold of 0.05.
Results
Study Characteristics
We collected and manually curated a total of five expression
profile studies in human ALS and SOD1G93A mice, compris-
ing a total of nine datasets (Table 1). In particular, we used
human genomic data published in our previous work, where
we analyzed whole-genome expression profiles of 41 motor
cortex samples of control (10) and sporadic ALS (31) patients.
By using an unsupervised hierarchical clustering algorithm,
we were able to separate, on the basis of their transcriptome
profiles, control from SALS patients, subdividing these latter
into two different groups (SALS1 and SALS2), each associ-
ated to specific differentially expressed pathways and genes
(Aronica et al. 2015). Interestingly, the analysis of altered
networks of biological molecules in SALS provided a number
of potential therapeutic targets, which could be used to inter-
fere with ALS pathogenesis (Aronica et al. 2015; Morello and
Cavallaro 2015).
The present analysis focused on the expression changes of
70 target genes previously characterized in SALS patients (33
differentially expressed in SALS1 and 54 in SALS2 patients),
together with their corresponding homologs in SOD1G93A
mice, using data present in public repositories (Fig. 2a,
Supplementary Table 1 and Supplementary Figs. 1a and 2a)
(Ferraiuolo et al. 2007;Maximino et al. 2014; deOliveira et al.
2013; Saris et al. 2013; Kudo et al. 2010). All animal studies
were performed on spinal cord samples and included a total of
74 samples (37 from SOD1G93A mice and 37 from littermate
control mice). One of these studies applied the technique of
laser capture microdissection (LCM) to isolate motor neurons
from surrounding tissues, performing a cell-specific analysis
for the identification of motor neuron-specific changes
(Ferraiuolo et al. 2007; Saris et al. 2013). Another study
(GSE56926) was carried out at a single time point (60 days),
while others (GSE10953, GSE50642, and GSE27933) includ-
ed multiple time-course data points. In total, seven time points
were used in this study, which can be grouped into three dif-
ferent stages of disease: Bpre-symptomatic^ (40–60 days),
Bsymptomatic^, characterized by early clinical signs of ALS
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stage (100–120 days) based on ALS symptom progression.
The main features of studies included in this meta-analysis
are summarized in Table 1.
Identification of Commonly Deregulated Drug Targets
Both in Terminal Stage SALS Patients and SOD1G93A
Mice
After data processing, as indicated in the BMethods^ section,
an Baggregate dataset^ was generated. It includes the expres-
sion changes of 70 deregulated genes, encoding potential ther-
apeutic targets previously characterized in SALS patients, to-
gether with those of their corresponding homologs in
SOD1G93A mouse at different ages and stages of disease.
Subsequently, to investigate and select candidate genes con-
sistently conserved between postmortem human samples and
end-stage ALS mouse models, we compared expression pro-
files of these 70 genes in SALS patients with those observed
in terminal stage SOD1G93A mice (Fig. 2a, Supplementary
Table 1, and Supplementary Figs. 1a and 2a) (Aronica et al.
2015; Morello and Cavallaro 2015). From this comparison, 19
statistically significant genes emerged as deregulated both in
mice and SALS patients: 9 commonly altered with SALS1
and 16 with SALS2 patients (Fig. 2b, c, Table 2, and
Supplementary Figs. 1b and 2b). Although some of these
genes (7/19) were differentially deregulated between mice
and SALS patients, the majority of them (12/19) were
deregulated in the same direction in end-stage SOD1G93A
mice and in at least one of SALS patient subgroups, suggest-
ing the existence of similar pathogenic mechanisms shared by
both species (Table 2).
Time-Course Analysis of Commonly Deregulated Drug
Target Genes in SALS Patients and SOD1G93A Mice
at Different Stages of Disease
Deregulation of candidate genes in both human postmor-
tem tissues and terminal stage SOD1G93A mouse samples
may be due to reactive changes that occur in final stages
of disease, such as cell death and reactive immune re-
sponses. To better evaluate whether gene expression
changes were a consequence of motor neuron degenera-
tion, we analyzed the expression of drug targets in
SOD1G93A mice at different time points (Fig. 3 and
Supplementary Figs. 3 and 4). Results obtained showed
that, in the majority of cases, their deregulation occurs in
animals between 70 and 80 days of age, contestually with
the appearance of the first disease symptoms. In three
cases (e.g., Atxn1, Fgfr2, Tubb5), gene expression chang-
es started long before symptom onset (40–60 days of
age).
Functional Annotation Clustering of the Most Promising
Targets
To better understand the biological role of candidate drug
targets in ALS pathophysiology, we performed a GO enrich-
ment analysis. The most relevant GO terms were grouped into
the three macro-categories: biological processes (BP), molec-
ular functions (MF), and cellular components (CC). The top
10 enriched categories associated with candidate targets are
summarized in Fig. 4b–d and mainly included: GO terms for
biological processes connected to regulation of adaptive im-
mune response (GO:0002819, P = 6.91E−09) and positive reg-
ulation of cell proliferation (GO:0008284, P = 6.91E−09),
while for molecular functions, the enriched GO terms were
receptor binding (GO:0005102, P = 4.32E−07) and growth
factor binding (GO:0019838, P = 1.37E−03) and, for cellular
component, the enriched GO terms were cell surface
(GO:0009986, P = 2.49E−06) and cel l per iphery
(GO:0071944, P = 1.25E−05) (Supplementary Tables 2, 3,
and 4). GO enrichment analysis was also used to define the
relationship between target genes and corresponding GO cat-
egories and was represented through a hierarchical clustering
in which genes were grouped according to their semantic sim-
ilarities (Fig. 4a).
To further investigate the biological significance of prom-
ising candidate targets, we performed pathways enrichment
analysis by using functional ontologies represented in
Metacore repository. This analysis revealed apoptosis, inflam-
mation, immune response, and cell adhesion as the most high-
ly enriched pathways by the candidate drug target list (Fig. 5
and Supplementary Table 5). Based on functional enrichment
analysis, we also built a comprehensive pathway map restrict-
ed to only direct interactions among the 12 most promising
candidate targets and their pharmacological modulators
(Fig. 5).
Discussion
ALS is a progressive and incurable neurodegenerative disease
(Pasinelli and Brown 2006; Ferraiuolo et al. 2011). The clin-
ical translational failure of apparently promising preclinical
studies conducted in animals may be partly explained by the
inadequate nature of these monogenic disease models to mim-
ic the complexity of human pathology (Turner et al. 2001).
This underlines the importance to identify common molecular
features between animal models and human ALS, allowing
the consequent selection and prioritization of the most prom-
ising targets for successful therapeutic testing.
In this paper, we choose a meta-analysis approach to com-
pare gene expression profiles, extracted from microarray
datasets of SALS patients with those obtained in SOD1G93A
mice, in order to select targets that were differentially
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expressed, in a statistical manner, both in humans and mouse
model. To this end, we used the human dataset identified in
our previous study (Aronica et al. 2015), restricting the anal-
ysis only to genes previously recognized as potential thera-
peutic targets together their homologs in mouse model
(Fig. 2a and Supplementary Table 1) (Ferraiuolo et al. 2007;
Maximino et al. 2014; deOliveira et al. 2013; Saris et al. 2013;
Kudo et al. 2010). Results obtained demonstrated that the
majority of these drug target genes (12) were statistically
deregulated in the same direction in both mice and SALS
patients (Fig. 2b, c and Table 2), suggesting that similar mo-
lecular mechanisms are shared by both species. Nevertheless,
7/12 genes (CDK5, FGF1, GABRA1, IL6ST, NTRK2(TRKB),
SEMA3A, TLR4) were differentially deregulated between
mice and SALS patients, representing species-specific mech-
anisms controlling motor neuron death (Table 2).
In accordance with the aim of this work, we focused the
analysis on genes that, being similarly deregulated in human
and mouse, are promising candidates for preclinical testing.
To investigate the biological role of these drug target genes,
568 J Mol Neurosci (2017) 61:563–580
we performed an integrated GO and Pathway Maps enrich-
ment analysis that revealed a number of processes and path-
ways similarly and significantly altered both in affected pa-
tients and mice. In particular, the majority of selected targets
were involved in common functional pathways, such as im-
mune response, inflammation, cell adhesion, apoptosis, and
cell survival, providing additional evidence for the involve-
ment of these processes in the pathophysiology of ALS
(Figs. 4 and 5).
In the following paragraphs, we will discuss the 12 most
promising candidate drug target genes and highlight their po-
tential relevance for ALS therapy.
Ataxin-1
Ataxin-1 (ATXN1 or SCA1) encodes a nuclear protein in-
volved in several cellular processes, including protein folding
and degradation, mRNA processing, transcriptional regula-
tion, and oxidative stress. ATXN1 normally contains a
polyglutamine (polyQ) tract with 22–23 repeats, while the
expanded polyQ (23–34 repeats) produces a mutant misfolded
protein that tends to form insoluble aggregates into the nucle-
us, leading to neuronal dysfunction and cell death. In addition
to being the cause of spinocerebellar ataxia 1 (SCA1), this
gained number of polyQ repeats may also increase genetic
risk for ALS (Conforti et al. 2012). In the present study, we
found a downregulated expression of ATXN1 in SALS2 pa-
tients and a decreased expression of its mouse homolog
(Atxn1) in SOD1G93A mice at a presymptomatic stage
(~60 days of age) (Figs. 3b and 5). These results are in line
with the evidence that the loss of ataxin-1 function leads to
neurological alterations in synaptic plasticity and motor defi-
cits through the altered expression of many genes regulated by
ATXN1-dependent transcription, including the PolyQ binding
protein-1 (PQBP-1), dopamine receptor D2 (DRD2), RNA
polymerase I, and Wnt signaling, all of them also altered in
SALS patients (Aronica et al. 2015; Okuda et al. 2003; Matilla
et al. 1998; Crespo-Barreto et al. 2010). These data suggest
that the alteration of ATXN-1 functions may be involved in
the development of both sporadic and familial ALS, in the
early stage of disease, making ATXN-1 a promising candidate
for disease treatment (Morello and Cavallaro 2015). Among
the agents able to prevent aggregation of the mutant ataxin-1
and the consequent neurotoxicity, bromocriptine methylate
(BRC), a potent DRD2 agonist approved for the treatment of
Parkinson’s disease, showed promising results in ALS pre-
clinical studies (Tanaka et al. 2011; Hearst et al. 2010).
Indeed, intraperitoneal administration of BRC in mutant
SOD1 mouse confers neuroprotection, sustains motoneuronal
functions, slows disease progression, and prolongs survival
interval after disease onset, mainly through suppression of
oxidative stress-induced cell death. Based on these promising
results, this drug is currently being examined in phase IIa
clinical trials in patients with ALS (Nagata et al. 2016).
Overall, further studies are needed to better deepen the poten-
tial therapeutic effects of this and other ATXN-1 pharmaco-
logical modulators for ALS treatment (Fig. 5).
Interleukin-8 Receptor Type B
Chronic inflammation and immune response abnormalities
are two processes that may greatly contribute to the progres-
sion of ALS disease (Aronica et al. 2015; McCombe and
Henderson 2011). A critical component of the inflammatory
response is the chemokine (C-X-C motif) receptor 2
(CXCR2), also known as interleukin-8 receptor type B
(IL8B), a chemokine receptor involved in microglia activation
and neuroinflammatory cascade. Increased expression of
CXCR2 and its rodent homolog (Cxcr2) were found, respec-
tively, in SALS2 patients and SOD1G93A mice at a symptom-
atic stage (80–100 days of age), suggesting that inflammatory
chemokine signaling may exert pathogenic effects both in
human and mouse ALS (Figs. 3b and 5). These data are cor-
roborated by recent in vitro studies showing that the activation
of CXCR2 and its ligand IL-8 induces neurotoxicity and di-
rectly contributes to motor neuron degeneration (De Paola
et al. 2007). The modulation of CXCR2 may thus represent
a potential neuroprotective strategy in ALS therapy. In fact,
Fig. 2 Meta-analysis of gene expression profiles of SOD1G93A mice and
SALS patients reveals common candidate therapeutic targets. a
Hierarchical clustering heat map visualization of the gene expression
pattern for 70 promising therapeutic targets across different datasets of
SOD1G93A mice (at different ages and stages of disease) and SALS
patients. In this two-dimensional presentation, rows represent target
genes and columns denote datasets used in our meta-analysis. From left
to right, these datasets included expression profiles ofmotor neurons from
spinal cord of SOD1G93A mice at 40, 60, 70, 80, 90, 100, and 120-day old
and motor neurons from motor cortex of two SALS patients’ subgroups.
Gene symbols for each human/mouse ortholog pair are shown on the
right hand side of the picture. Genes were clustered using a hierarchical
clustering based on Euclidean distances of average fold change values
represented in linear scale and with complete linkage method as
parameter. In the dendrograms shown (left), the length and the
subdivision of the branches display the relatedness of the expression of
the genes. Fold change values were calculated as the ratio between SALS
patients versus individual controls for the human dataset and between
SOD1G93A mice versus littermate control groups for each murine
dataset. As shown in the color bar, red indicates upregulation, green
downregulation, and black no change. Complete gene list and
corresponding fold change values are found in Supplementary Table 1.
b Hierarchical clustering of 19 statistically significant (P value <0.05)
differentially expressed target genes commonly deregulated in both
end-stage SOD1G93A mice and SALS patients. Genes corresponding to
each row of the heat map are on the right hand side of the picture. Genes
are arranged in a hierarchical cluster based on their expression patterns,
combined with a dendrograms (left) whose branch lengths reflect the
relatedness of expression patterns. As shown in the color bar, red
indicates upregulation, green downregulation, and black no change. c
Venn diagrams of statistically significant differentially expressed target
genes in 120-day-old SOD1G93A mice and SALS patient subgroups
compared to their corresponding controls (Table 2)
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pharmacological antagonism of CXCR2 produced neuropro-
tective effects in different animal models of neurodegenerative
diseases, including Alzheimer’s, by attenuating chemokine
receptor expression in microglia, inhibiting receptor-
Fig. 3 Time-course analysis of commonly deregulated genes in both
SALS patients and SOD1G93A mice at different stages of disease. Plots
illustrate the correlation of expression fold changes (y-axis) of target
genes between SALS1 patients (a) and SALS2 patients (b) versus
individual controls and SOD1G93A mice versus littermate controls at 40,
60, 100, and 120 days of age (x-axis). For generating time-course analysis
of SOD1G93A mice, we referred to following datasets: GSE10953 for 60,
90, and 120 days old, GSE50642 for 40 days old, and GSE27933 for
100 days old, respectively. The expression pattern relative to SALS
patients was reported to the far right of the graph. Each point represents
the average fold change value of all probe sets representing the gene. As
shown in the color bar, red indicates upregulation and green
downregulation. The blue solid line represents the regression line and
the surrounding gray area indicates the 95% confidence interval.
Source data for this figure are available on Supplementary Table 1
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mediated inflammatory reactivity and enhancing neuronal vi-
ability (Marsh and Flemming 2011; Ryu et al. 2015; Gorio
et al. 2007). Several pharmacologic agents blocking CXCR2
(e.g., reparixin, navarixin, elubrixin, SB332235) are currently
tested in preclinical or clinical trials as anti-inflammatory
agents and, among these, reparixin has shown neuroprotective
effects in primary cultured motor neurons (Morello and
Cavallaro 2015; De Paola et al. 2007). Based on these prom-
ising results, we believe that drugs attenuating CXCR2-
mediated neurotoxicity may confer neuroprotection against
the inflammatory cascade and oxidative damage in ALS path-
ogenesis (Fig. 5).
Epidermal Growth Factor Receptor
Epidermal growth factor (EGF) is a potent mitogenic factor
that, by activating the EGF receptor tyrosine kinases
(EGFR/ErbB), stimulates proliferation, survival, maturation,
Fig. 4 Hierarchical clustering and GO functional enrichment analysis of
candidate target genes. a Heat map with hierarchical clustering based on
Gene Ontology (GO) semantic similarity score of the 19 most promising
selected target genes is visualized along with their expression profiles. In
this two-dimensional representation, each row represents a single target
gene and each column a sample from SOD1G93A mouse models at
different stages of disease and SALS patients. Gene symbols for each
human/mouse ortholog pair are shown on the right hand side of the
picture. Red blocks represent upregulation and green blocks
downregulated expression of the relative transcripts, black no change.
b–d Pie charts representing the top 10 enriched (P < 0.05) GO terms
for the 12 commonly deregulated targets between SALS patients and
SOD1G93A mice. The GO terms were subdivided into three GO
categories: (b) biological processes, (c) molecular functions, and (d)
cellular components. Enrichment analyses were performed using the
Enrichment Analysis tool in MetaCore. GO terms or biological features
of differently expressed target genes and the percentage of genes
represented in each category are indicated. More detailed information
are provided in Supplementary Tables 2, 3, and 4
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and migration of a variety of neurons as well as migration,
invasion, and proliferation of astrocytes (Kajiwara et al.
2003). Several lines of evidence suggested that the EGFR
signaling pathway could play a role in the pathophysiology
of many neurodegenerative diseases, including ALS (Offen
et al. 2009). In fact, EGFR activation triggers quiescent astro-
cytes into reactive astrocytes, promoting the neurodegenera-
tive process (Liu et al. 2006). Increased expression of EGFR
mRNA observed both in SALS2 patients and SOD1G93A
mouse models could thus be related to the reactive astrogliosis
surrounding degenerating motor neurons (Figs. 3b and 5)
(Vargas and Johnson 2010), and pharmacological inhibition
of EGFR signaling cascade may represent a strategy to slow
progression of ALS. Treatments with EGFR inhibitors, clini-
cally used in oncology, were reported to be neuroprotective in
many models of neuronal injury (Mizuno et al. 2013). In par-
ticular, some of these compounds (erlotinib, genistein,
masoprocol) have shown positive results in ALS preclinical
studies, delaying disease onset (Boston-Howes et al. 2008;
Trieu and Uckun 1999). Another important exponent of this
drug class, suramin, is currently in preclinical phase for some
neurodegenerative disease, like Alzheimer’s and Parkinson’s
(Chan and Lin-Shiau 2001; Heneberg 2009). Besides its ac-
tivity as EGF inhibitor, suramin also contrasts neurotoxicity
mediated by nitric oxide synthase (NOS), histone deacetylase
(HDAC), and P2Y2 (Xu et al. 2011; Goureau et al. 1993),
three proteins that were already extensively implicated in
ALS (Janssen et al. 2010; Carlesi et al. 2011). Although the
role of EGFR in the pathophysiology of ALS has not been
fully clarified, the promising results obtained from the
abovementioned and other EGFR inhibitors (e.g., PKI166,
BMS690514, canertinib, gefitinib, PD153035) make them at-
tractive candidates for further preclinical studies (Fig. 5).
Fas Ligand
Fas ligand (FasL or CD95L) is a member of the tumor necro-
sis factor (TNF) superfamily that activates a cascade several
mediators involved in neuroinflammation and apoptotic cell
death, such as caspases, p38 kinase and nitric oxide, contrib-
uting to mechanisms of neuronal loss and neuritic degenera-
tion. Deregulation of FASL signaling has been associated with
the pathogenesis of several neurodegenerative diseases, in-
cluding ALS (Aronica et al. 2015; Morello and Cavallaro
Fig. 5 Enrichment analysis for pathway map ontologies revealed
significant biological processes associated with the most promising
targets commonly deregulated in mouse and human ALS. a
Representation of the top 10 most significantly enriched (P value <0.05)
canonical pathway maps associated with the most promising target genes
commonly differentially expressed in end-stage SOD1G93A mice and
SALS patients when compared with their corresponding controls. A
histogram of statistical significance (−log P value) is shown: the list is
arranged in descending order with the most significant pathways at the
top. The analysis was performed using the MetaCore™ pathway analysis
suite. Detailed information about pathway map enrichment analysis is
described in Supplementary Table 5. b Interaction pathway map
representing the 12 most promising targets deregulated in the same
direction in both end-stage SOD1G93A mice and at least one of the two
subgroups of SALS patients, together with their corresponding
pharmacological modulators. The map was created using the MetaCore
Pathway Map Creator tool (GeneGo). Gene expression values are
presented on the map as Bthermometer-like^ figures (red for upregulated,
blue downregulated with thermometer height relative to fold change) with
SALS1 patients data represented as thermometer no. 1, SALS2 patient no.
2, and 120-day old SOD1G93A mice no. 3. Pathway objects and links are
described separately in the Supplementary Fig. 5
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2015; Raoul et al. 2006; Aebischer et al. 2013; Petri et al.
2006; Cavallaro and Calissano 2006). Indeed, a growing body
of data has provided in vivo evidence for the involvement of
this cell death pathway in motor neuron death in presymptom-
atic ALS transgenic mice overexpressing different SOD1 mu-
tations (G37R, G85A, G93A). In accordance with these ob-
servations, we found increased expression of the gene
encoding FasL in SALS2 patients and SOD1G93A mice on
day 70, before the development of motor impairment, suggest-
ing a role of FasL as a possible target for treating ALS in the
early stage of the disease (Figs. 3b and 5). A relevant number
of therapeutic agents are being developed to interfere with the
FasL signaling pathway, conferring neuroprotection against
oxidative stress and inflammatory processes. Among these,
lenalidomide, a potent immunomodulatory agent that reduces
the FasL expression and inactivates downstream effector
caspases, has shown to extend the survival of ALS transgenic
mice (Neymotin et al. 2009). These data encourage the future
clinical evaluation of lenalidomide and other FasL inhibitors
as possible therapeutic strategies to prevent or slow ALS dis-
ease progression.
Fibroblast Growth Factor Receptor 2
The fibroblast growth factors (FGFs) constitute a family of
multifunctional proteins that mediate various cellular re-
sponses, such as neurons and oligodendrocyte proliferation,
migration, and differentiation as well as central nervous sys-
tem development. Their effects are mediated through a sub-
family of tyrosine kinase receptors, named FGF receptors
(FGFRs). In humans, four FGFRs are described, including
FGFR2 subtype. The aberrant activity of FGFs and their re-
ceptors, either through gain or loss of function, has been in-
volved in different neuropathological conditions, including
ALS. In particular, previous studies showed that FGF-1, re-
leased from motor neurons in response to oxidative damage,
induces accumulation of its receptors and activation of astro-
cytes that, in turn, initiate the cascade of events that leads to
motor neuron death in ALS (Cassina et al. 2005; Petri et al.
2009; Huang et al. 2012). On the other hand, a significant or
complete loss of FGF signaling seems to induce demyelin-
ation and axonal damage, contributing to the neurodegenera-
tive and neuroinflammatory processes underlying ALS (Kang
et al. 2014). In agreement to these studies, we observed the
differential expression of genes encoding FGFs and its recep-
tor FGFR2 in SALS patients (Fig. 5). In addition, a decreased
expression of their mouse homologs was found in SOD1G93A
transgenic mice, starting on 60–70 days of age and
progressing with the advance of disease (Fig. 3b).
Pharmacological modulation of FGF/FGFR signaling path-
way may thus represent a good therapeutic strategy to contrast
neuroinflammatory processes in ALS. The selective FGFR
tyrosine kinase inhibitor, PD166866, prevents motor neuron
death in ALS mouse models, by reducing astrocyte activation
and oxidative damage (Cassina et al. 2005), suggesting the
potential therapeutic role of this and other FGF/FGFR signal-
ing inhibitors (orantinib, brivanib, dovitinib, suramin, pento-
san polysulfate) in ALS (Fig. 5). Similarly, functional FGFR
peptide agonists (e.g., FG Loop (FGL) peptide) seem to be of
therapeutic interest for ALS due to their effects not only on
neurogenesis but also on synaptic formation, neuron–glia in-
teractions, and inflammation (Woodbury and Ikezu 2014;
Ohta et al. 2006; Li et al. 2010; Cox et al. 2013). Further
studies are needed to better clarify the involvement of FGF/
FGFR signaling in ALS pathophysiology and its role as a
future therapeutic target for ALS (Fig. 5).
AMPA Glutamate Receptor 2
Enhancement of calcium influx through the GluR2 subunit of
the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate
(AMPA) ionotropic glutamate receptor and the consequent
excitotoxicity represent the main plausible hypotheses for se-
lective neuronal death in ALS (Shaw and Ince 1997; Takuma
et al. 1999; Kwak and Kawahara 2005). Aberrant expression
of GluR2 accelerates the degenerative process of motor neu-
rons and shortens lifespan of ALS transgenic mice (Tateno
et al. 2004). Although in SALS2 patients we observed de-
creased expression of the gene encoding GluR2 subunit
(GRIA2), its homolog showed a biphasic deregulation in
SOD1G93A transgenic mice, being upregulated at 60 days of
age (presymptomatic stage) and drastically downregulated lat-
er, in parallel to the development of motor deficits (Figs. 3b
and 5). This discrepancy may be explained considering that, at
the presymptomatic stage, high abundance of GluR2 exposes
motor neurons to a greater Ca2+ excitotoxicity mediated
through AMPA receptors, while downregulation of GluR2
observed during the symptomatic phase could reflect a tran-
sient mechanism of excitotoxicity caused by an imbalance of
excitatory–inhibitory synaptic functions that precede motor
neuron death (Schutz 2005). Based on these observations,
pharmacological strategies aimed to decrease glutamate-
mediated neurotoxicity and restore Ca2+ homeostasis could
be useful for treatment of ALS patients. To this end, the use
of some AMPA receptor antagonists (e.g., ZK 187638,
NBQX, GYKI-52,466) has been tested and shows promising
results in ALS preclinical studies. Indeed, they showed neu-
roprotective effects by improving motor functions and
prolonging the survival of ALS mouse models (Tortarolo
et al. 2006; Van Damme et al. 2003; Albo et al. 2004).
Unfortunately, another AMPA receptor antagonist,
talampanel, which showed promising results in preclinical
studies (Paizs et al. 2011), was ineffective when tested in
patients (Pascuzzi et al. 2010). Differential expression of
AMPA receptor subunits between the two subgroups of
SALS patients, as demonstrated previously (Aronica et al.
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2015), may contribute to explain this clinical failure. In light
of this evidence, further investigations are needed to verify
the potential clinical benefits of talampanel and other AMPA
receptor antagonists for the personalized treatment of ALS
patients (Fig. 5).
Major Histocompatibility Complex Class I
Deregulation of the antigen processing and presentation path-
ways is considered a possible cause of the harmful non-
autonomous cell toxicity occurring during ALS pathology.
Among the main mediators of this inflammatory signaling
cascade, of great relevance are the molecules belonging to
the major histocompatibility complex (MHC) class I, a large
family of proteins encoded by a complex of genes, such as
HLA-A, HLA-B, and HLA-C. In particular, an increased ex-
pression of these proteins and their murine homologs has been
found in the spinal cord of ALS patients and microglia sur-
rounding motor neurons of presymptomatic ALS animal
models, respectively (Lampson et al. 1990; Graber et al.
2010; Casas et al. 2013). In line with these findings, we found
upregulated expression of genes encoding MHC class I mol-
ecules, particularly HLA-A, in the motor cortex of SALS1
patients and a similar expression was observed in samples
from SOD1G93A transgenic mouse models at presymptomatic
stages (70–80 days of age) (Figs. 3a and 5). All these data
contribute to highlight the role of MHC class I molecules in
increasing ALS susceptibility, supporting their possible role as
targets for limiting neurodegeneration in this disease (Fig. 5).
Glatiramer acetate (GA) is an immunomodulator agent able to
reduce the MHC class I expression as well as bind to the
neuronal and glial MHC molecules expressed in the central
nervous system and influencing communication between such
cells. This drug, clinically used to treat multiple sclerosis, was
reported to exert a neuroprotective role in several neurological
conditions, including ALS (Scorisa et al . 2011).
Administration of GA, in fact, delays disease onset and pro-
g ress ion in ALS an imal mode l s by dec reas ing
neuroinflammatory processes and contributing to reduce the
loss of synaptic inputs to motor neurons occurring during the
disease (Habisch et al. 2007). Phase II clinical trials for GA are
currently conducted in ALS patients (Gordon et al. 2006).
Interleukin-10
Interleukin 10 (IL-10) is a potent anti-inflammatory cytokine
involved in mechanisms of immunomodulation and maintain-
ing the anti-inflammatory environment within the central ner-
vous system. There is a strong body of evidence demonstrat-
ing the neuroprotective role of this factor against motor neuron
injury in ALS (Xin et al. 2011). Accordingly, downregulation
of the gene encoding IL-10 was observed in SALS2 patients,
while the expression of its homolog in SOD1G93A mice
was stable but with lowest values as compared to their
relative littermate controls (Figs. 3b and 5). Based on
these observations, pharmacological modulation of IL-10 sig-
naling may represent a promising strategy for the treatment of
ALS. To this regard, it is interesting to note that glatiramer
acetate, besides its activity as MHC modulator (discussed
above), exerts its anti-inflammatory effects also by inducing
T helper cells to secrete IL-10 and other anti-inflammatory
cytokines, providing a multi-targeted mechanism of action
for the treatment of ALS (Arnon and Aharoni 2004; Vieira
et al. 2003).
Janus Kinase 3
The family of Janus kinases comprises four tyrosine kinases
(JAK1, JAK2, JAK3, and TYK2) which together with the
family of signal transducer and activator of transcription
(STAT) plays key roles in numerous cytokine-mediated sig-
naling pathways. Deregulation of this signaling pathway has
been widely associated with numerous neuroinflammatory
and neurodegenerative diseases, including ALS (Aronica
et al. 2015; Nicolas et al. 2013). In particular, differential
expression of genes encoding JAKs has been found in the
motor cortex of SALS patients (Fig. 5). In addition, the ex-
pression of Jak3 in SOD1G93Amicewas found to be low in the
first 60 days of age but then increased with the disease pro-
gression and paralysis development, peaking on day 120, just
before death (Fig. 3a). These results imply the blockade of
JAK-STATsignaling and, in particular, those of JAK3 activity,
as a promising therapeutic strategy to contrast the degenera-
tive progression of ALS, especially for patient subtypes asso-
ciated with aberrant activation of this pathway. In support of
this theory, several studies showed neuroprotective effects of
JAK inhibitors (Ignarro et al. 2013). Among these,WHI-P131
treatment exhibited promising results in ALS preclinical stud-
ies, slowing disease progression and increasing survival of
ALS transgenic mice (Trieu et al. 2000). Further studies are
still necessary to confirm the therapeutic potential of WHI-
P131 and other JAK inhibitors (e.g., AG490, AZD1480) in
ALS therapy (Fig. 5).
Matrix Metalloproteinase 2
Matrix metalloproteinases (MMPs) are a large family of
calcium-dependent zinc-containing endopeptidases exerting
important functions in several cellular processes, including
synaptic remodeling, degradation of the extracellular matrix,
and neuronal regeneration (Singh et al. 2015). In agreement to
these evidences, deregulation of MMP system is thought to
contribute strongly to the development of many neurodegen-
erative diseases, including ALS (Brkic et al. 2015; Niebroj-
Dobosz et al. 2010). The upregulation of different MMP-
mRNAs, such as MMP-2, both in SALS2 patients as well as
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in SOD1G93A mice, supports the role of MMP-signaling cas-
cade as a promising therapeutic target for ALS (Figs. 3b and
5). Indeed, pharmacological inhibition of MMP expression,
synthesis, and activity has shown beneficial effects in various
neurodegenerative conditions (Jarvelainen et al. 2009).
Among the agents able to reduce MMP2 levels, particular
attention should be given to the drug thalidomide, a potent
anti-inflammatory agent that has shown promising results
both in preclinical and clinical ALS studies (Kiaei et al.
2006; Stommel et al. 2009). Despite its use as therapeutic
agent for ALS treatment, however, it presents several impor-
tant side effects. To overcome this limit, other MMP inhibitors
(e.g., marimastat, tanomastat, batimastat, ONO4817, doxycy-
cline, rebimastat, pravastatin, S3304, halofuginone, melpha-
lan) have been developed and many of these, currently tested
in preclinical or clinical trials as therapeutic agents in oncolo-
gy, have also demonstrated therapeutic effects for several neu-
rodegenerative diseases, such as Alzheimer’s (Costa et al.
2011; Dong et al. 2009). These encouraging results make the
MMP inhibition a possible therapeutic strategy to treat ALS
disease (Fig. 5).
Tubulin Proteins
Among the main components of the cytoskeleton are micro-
tubules, cytoskeletal filaments composed of heterodimers, in-
cluding α/β-tubulin. Tubulin beta proteins (TUBBs) are high-
ly expressed in neurons where they play an important role
both in neurogenesis and development as well as axon guid-
ance and maintenance. Recent evidence indicates that disrup-
tion of tubulin beta system in motor neurons, through oxida-
tive damage, may affect their interaction with other important
proteins, such as dynein, interfering with the stability and
function of microtubules (Millecamps and Julien 2013). In
particular, aberrant expression and aggregation of TUBB pro-
teins were found in the spinal cord of mutant SOD1G93A mice
before the onset of symptoms (Lederer et al. 2007a; Kabuta
et al. 2009). In accordance with these results, we observed the
differential expression of genes encoding TUBB1/TUBB6 in
SALS patients and the altered mRNA expression of their mu-
rine homologs (Tubb5 and Tubb6) in SOD1G93A mice at a
presymptomatic stage. These data suggest a potential causa-
tive role of TUBB system in the early events of ALS progres-
sion (Figs. 3 and 5). Pharmacological approaches aimed to
functional recovery of tubulin system might contribute to re-
store the axonal transport defects and altered nerve signals in
ALS. This hypothesis is sustained by several studies that high-
light as taxanes (paclitaxel, docetaxel) and other microtubule-
targeting drugs (batabulin, vinorelbine, ABT751), mainly
used in oncology treatments, also show neuroprotective ef-
fects. Indeed, they restore impaired transmission of nerve im-
pulses in many neurodegenerative diseases, including
Alzheimer’s (Shemesh and Spira 2011). Despite their clinical
efficacy, these drugs may induce neurotoxic damages and,
thus, several other compounds have been developed to pre-
vent side effects. One representative agent of these new drug
class is olesoxime, a neuroprotective and reparative com-
pound, targeting tubulins, which reduces astrogliosis and
microglial activation, inducing neurite outgrowth and improv-
ing nerve cell remyelination, promotes axonal sprouting, and
prevents the activation of the mitochondrial apoptotic path-
way, delaying disease onset and improving survival in ALS
animal models (Sunyach et al. 2012; Bordet and Pruss 2009).
Although ALS phase II/III clinical trials with olesoxime
showed disappointing results, this failure may be due to the
lack of a molecular-based recruitment of ALS patients in spe-
cific subgroups, as well as to a problem of intervening time
between starting drug treatment and the stage of the disease,
rather than an absence of its therapeutic efficacy (Martin 2010;
Lenglet et al. 2014). Further studies are needed to evaluate the
potential therapeutic efficacy of olesoxime and other related
compounds in the early phases of ALS progression.
Conclusions
One of the major problems associated with the develop-
ment of effective ALS treatments is the inadequacy of the
animal models (Turner et al. 2001). Indeed, despite the
wide use of mouse models for ALS in biomedical re-
search, they would mimic only partial aspects of human
pathology, often leading to a consistent lack of concor-
dance between the preclinical and clinical studies.
Although the role of some potential candidate targets in
ALS pathogenesis has been studied in detail in individual
studies, no integrated analysis has previously elucidated
which potential drug targets are consistently deregulated
in both human and animal pathology. Therefore, a better
understanding of the similarities and differences between
the animal and human ALS pathophysiology is of funda-
mental importance to the rational identification of thera-
peutic interventions capable of stopping or at least effec-
tively modifying the course of ALS.
Here, we used a meta-analysis approach to identify poten-
tial drug targets commonly altered both in mouse and human
ALS, to optimize future preclinical investigations. Our inter-
species comparison demonstrated that candidate target genes
in mouse models exhibit expression patterns similar those of
the human conditions. In the same way, more pathways relat-
ed to these target genes were commonly deregulated, reveal-
ing the existence of a conserved transcriptional signature un-
derlying ALS neurodegeneration.
In addition to identify new potential pharmacological tar-
gets, our analysis proposes to offer a rational approach for
Bdrug repositioning.^ In fact, in light of the emerging molec-
ular taxonomy of SALS patients, many known drugs that were
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abandoned at clinical stages because of their low efficacy and/
or toxicity may be reevaluated for their potential therapeutic
role, with the consequent possibility to reduce both the time
and costs associated with drug discovery and development.
Despite our remarkable efforts in data collection, pro-
cessing, and integration using advanced statistical analysis
and data visualization tools, a limitation of the present
study is the relatively small number of datasets (nine)
used. Since these datasets have been generated by differ-
ent microarray platforms, species, disease stages, condi-
tions, and tissue types, it may be hard to identify reliable
disease-specific target genes. Finally, data obtained in the
murine model may not be able to accurately recapitulate
the extremely complex processes underlying human pa-
thology. In fact, although the SOD1G93A transgenic mouse
has been a bedrock for ALS research and the most impor-
tant and well-used model for well over a decade, it man-
ifests abnormal phenotypic features that might arise from
extreme SOD1 protein overexpression rather than being
the effect of the SOD1G93A mutation itself and motor
neuron death generally occurs over short periods of time.
This limits the subsequent translation of the results to the
human condition, where symptoms do not emerge for sev-
eral years and the disease develops through a combination
of multiple factors that are beyond genetic mutations and
currently not captured by any model.
Nevertheless, our study represents an important contribu-
tion in the field of ALS, not only supporting the utility of
SOD1G93A mice as animal models for both familial and spo-
radic ALS but also contributing to the selection of potential
candidates for the development of more accurate preclinical
studies and their effective translation into patient-oriented
clinical trials. In addition, it is interesting to note that
deregulated expression of the majority of candidate targets
was detected at onset of the disease, offering the possibility
to propose them for an early and more effective diagnosis and
therapy.
To our knowledge, this is the first meta-analysis-based
study that identifies drug target candidates by comparing
expression changes between mouse models and human
ALS. We believe that our findings could be considered
as starting point for future investigations for the develop-
ment of more effective therapeutic strategies for this dev-
astating disease.
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